Entropy Neurodynamics has expanded its global intellectual property portfolio with a South African patent for psilocybin-based fibromyalgia treatment, covering broad therapeutic methods and extending protection to 2043.
- South African patent granted for psilocybin fibromyalgia treatment
- Patent covers dosing, patient selection, clinical protocols, and manufacture
- Fibromyalgia market valued at US$1.9 billion in South Africa
- Patent protection extends until 2043 with annual renewals
- Strengthens Entropy’s global psychedelic IP strategy
Broad Patent Boosts Fibromyalgia Treatment IP
Entropy Neurodynamics (ASX:ENP) has been granted a South African patent that covers a comprehensive range of methods for treating fibromyalgia using psilocybin. The patent, officially titled "Methods of Treating Fibromyalgia with Compositions Comprising Psilocybin" (Patent No. 2025/01722), extends well beyond simple use claims to include dosing regimens, patient selection criteria, clinical assessment protocols, biomarkers, treatment outcome measures, integration therapy, and manufacturing processes.
This wide-ranging intellectual property protection is designed to provide significant commercial exclusivity as Entropy advances its psychedelic medicine platform. The patent's lifespan extends to 11 September 2043, subject to routine annual renewals, giving the company a long runway to capitalise on this therapeutic area.
Fibromyalgia: A Large Unmet Medical Need
Fibromyalgia is a chronic condition marked by widespread musculoskeletal pain, fatigue, sleep disturbances, and cognitive impairment. Affecting millions globally, it remains an area where current therapies often fall short. The South African market for fibromyalgia treatment was valued at US$1.9 billion in 2025, representing a substantial commercial opportunity for Entropy.
The patent grant aligns with Entropy’s broader strategy to secure protection across key jurisdictions and therapeutic indications. This approach aims to enhance the long-term commercial value of its psychedelic development programs, including its lead candidate TRP-8803, an intravenous formulation of psilocin.
Strategic Significance and Next Steps
CEO Jason Carroll emphasised that the patent strengthens Entropy’s position in fibromyalgia by protecting not just the use of psilocybin but the entire therapeutic framework. This includes dosing protocols and patient selection, which the company believes will be challenging for competitors to replicate.
As Entropy continues to generate clinical evidence for its precision-controlled psychedelic platform, building a robust global patent estate remains a strategic priority. The company views strong intellectual property as key to supporting future partnerships and reinforcing its commercial positioning in developing next-generation psychedelic therapies.
Entropy’s ongoing clinical programs, including Phase 2 trials for Binge Eating Disorder and Irritable Bowel Syndrome, have demonstrated promising results that feed into the development of TRP-8803, which aims to improve on the limitations of oral psilocybin by offering controlled onset, depth, and duration of the psychedelic experience. These developments provide a foundation for Entropy’s expanding IP portfolio and commercial ambitions.
Bottom Line?
Entropy’s South African patent adds a valuable layer to its IP moat in fibromyalgia, underscoring the company’s methodical build-out of psychedelic therapy protections across multiple markets and indications.
Questions in the middle?
- How will Entropy prioritise commercialisation strategies in South Africa versus other markets?
- What clinical milestones are expected next to support regulatory approval for fibromyalgia treatment?
- Could the broad patent claims face challenges from competitors or regulators in key jurisdictions?